E
Humacyte, Inc. HUMA
$1.33 $0.021.53% NASDAQ
Recommendation
Prev Close
$1.33
Volume
5,847,583
Avg Vol (90D)
5,126,440
Market Cap
$249.07M
Dividend & Yield
--
52-Week Range
$1.15 - $6.77
P/E (TTM)
--
EPS (TTM)
-$0.44
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Humacyte (HUMA) to Release Quarterly Earnings on Friday
11/7/2025 - MarketBeat
Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors
11/6/2025 - Zacks Investment Research
Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025
11/6/2025 - GuruFocus
Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025
11/6/2025 - Globe Newswire
Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
10/30/2025 - Zacks Investment Research
Humacyte announces publication of new data on Symvess
10/30/2025 - The Fly
Humacyte Announces Publication of New Data Comparing Symvess to Autologous Vein in Extremity Arterial Trauma
10/30/2025 - Globe Newswire
Weiss Ratings Reiterates Sell (E+) Rating for Humacyte (NASDAQ:HUMA)
10/26/2025 - MarketBeat
Humacyte, Inc. (HUMA) Surpasses Market Returns: Some Facts Worth Knowing
10/24/2025 - Zacks Investment Research
Humacyte, Inc. (NASDAQ:HUMA) Given Average Rating of "Moderate Buy" by Analysts
10/22/2025 - Ticker Report
Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why
10/17/2025 - Zacks Investment Research
Humacyte (HUMA): Valuation Insights Following Positive Ukraine Trauma Study Results
10/16/2025 - Simply Wall St
Humacyte, Inc. (HUMA) Advances While Market Declines: Some Information for Investors
10/14/2025 - Zacks Investment Research
BTIG Analyst Ryan Zimmerman Lowers Price Target for Humacyte (HUMA) HUMA Stock News
10/13/2025 - GuruFocus
Humacyte (NASDAQ:HUMA) Price Target Cut to $6.00 by Analysts at BTIG Research
10/13/2025 - MarketBeat
Humacyte price target lowered by $1 at BTIG, here's why
10/13/2025 - The Fly
Weiss Ratings Reiterates Sell (E+) Rating for Humacyte (NASDAQ:HUMA)
10/9/2025 - MarketBeat
Combat Trauma Study Results Might Change The Case For Investing In Humacyte (HUMA)
10/9/2025 - Simply Wall St
Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors
10/7/2025 - Zacks Investment Research
Humacyte Announces $60M Stock and Warrants Offering
10/7/2025 - TipRanks Financial Blog
Investors Buy High Volume of Call Options on Humacyte (NASDAQ:HUMA)
10/7/2025 - MarketBeat
Humacyte: Shares Tank On Fundraising News - What You Need To Know
10/7/2025 - SeekingAlpha
Humacyte (HUMA) Valuation in Focus After Encouraging Ukraine Trauma Results and New Patent Milestone
10/7/2025 - Simply Wall St
Humacyte (HUMA) Secures $60 Million in Stock and Warrant Offering
10/7/2025 - GuruFocus
Humacyte shares sink as it announces pricing of $60M direct offering
10/7/2025 - SeekingAlpha.com: All News
Income Statement
Total Revenue (TTM)
$818.00K
EBITDA (TTM)
-$103.92M
EBIT (TTM)
-$111.23M
Net Income (TTM)
-$58.66M
Balance Sheet
Total Assets (Q)
$138.80M
Total Debt (Q)
$83.96M
Total Liabilities (Q)
$134.74M
Book Value Per Share (Q)
$0.0259
Cash Flow
Cash from Operations (TTM)
-$104.50M
Cash from Investing (TTM)
-$1.79M
Cash from Financing (TTM)
$100.76M
Net Change in Cash (TTM)
-$5.53M
Filings
Filing Date
Monday, August 11, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 3 and 7 (est)
Price History
Loading...
Beta
1.94
7-Day Total Return
-17.90%
30-Day Total Return
-23.12%
60-Day Total Return
-29.26%
90-Day Total Return
-41.67%
Year to Date Total Return
-74.32%
1-Year Total Return
-76.99%
2-Year Total Return
-39.27%
3-Year Total Return
-58.82%
5-Year Total Return
--
52-week Low
Apr 08, 2025 - $1.15
52-week High
Dec 20, 2024 - $6.77
Valuation
Market Cap
$249.07M - Micro Cap
Enterprise Value
$295.00M
Price/Sales (TTM)
255.77
Price/Book (Q)
51.35
Dividends and Shares
Shares Outstanding
155.44
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
humacyte.com
Phone Number
919 313 9633
Address
2525 East North Carolina Highway 54
Durham, NC 27713
Country
United States
Year Founded
2004
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and... more
NASDAQ 11/07/2025 4:00PM Eastern Quotes delayed